An IRay of Hope: Stereotactic Radiosurgery for the Treatment of Wet AMD.-Dr. E. Mark Shusterman-02/05/2013 - 8:30am

Event Information
Event Topic: 
An IRay of Hope: Stereotactic Radiosurgery for the Treatment of Wet AMD.
Event Date: 
02/05/2013 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Dr. E. Mark Shusterman
Event Speaker Title: 
Medical Director
Event Speaker Company: 
Oraya Therapeutics, Inc
Event Speaker Bio: 

Mark Shusterman

Dr. E. Mark Shusterman has served as the Medical Director of Oraya Therapeutics, Inc., nearly since the company's founding six years ago. Oraya has developed, and is commercializing, an innovative radiation treatment for wet age-related macular degeneration, a common form of blindness which affects millions of people worldwide. Dr. Shusterman completed his undergraduate and medical education at the University of Rochester, and his post-graduate training included general, burn and plastic surgery. He has a passion for medical technology, which has led to full-time involvement in this arena. Prior to joining Oraya in 2007, Dr. Shusterman worked with companies in physiological monitoring, resorbable surgical fixation, bone regeneration, and soft tissue augmentation. In addition to his pursuits in medical technology, Dr. Shusterman also has a long-standing interest and training in aerospace medicine, and has been serving as a Flight Surgeon with the United States Air Force for the past 17 years. Additionally, he is the director of Interorbital Systems’ Space Medicine Advisory Board. IOS is a private orbital tourism and satellite delivery company, based in Mojave, CA.

Event Details
Event Details: 

Wet age-related macular degeneration (AMD) ranks among the top causes of blindness worldwide. It is a condition that affects millions of elderly people, and, if untreated, commonly results in near-total loss of central vision within a year or two of diagnosis. Wet AMD is characterized by abnormal and rapid growth of fragile blood vessels beneath the retina that results in hemorrhage, fluid accumulation, and ultimately scarring and permanent loss of photoreceptors. Although incurable, it can presently be managed with near-monthly injections of drugs that inhibit proliferation of new blood vessels. These very expensive compounds must be administered directly into the eye on a recurring basis, resulting in substantial burdens and risks to the patients, their families, healthcare systems, and payers. Oraya Therapeutics has built a device which delivers low-energy X-rays precisely to the small retinal target, allowing irradiation of the neovascular lesion without undesirable exposure to healthy eye structures. Clinical data indicate that the use of radiation in conjunction with existing pharmacologic therapies may have beneficial results in terms of improved disease control with a decreased need for recurrent intra-ocular injections. This presentation will provide an overview of wet AMD and Oraya's innovative technology.